Business Wire

AL-ADTRAN

16.5.2023 14:01:34 CEST | Business Wire | Press release

Share
Adtran expands Oscilloquartz PNT platform for enhanced protection of critical timing networks

Adtran today launched a major upgrade of its Oscilloquartz aPNT+ technology suite, bringing new levels of resilience to critical network infrastructure that relies on position, navigation and timing (PNT) services. With enhancements to its core, edge and access synchronization solutions, the portfolio provides operators of telecommunications, financial networks, power grids, defense infrastructure and more with the best available protection against GNSS vulnerabilities and cyberattacks. Adtran’s timing technology now leverages more sources of accurate and reliable timing and features new capabilities to detect disturbances and assure vital PNT services.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230512005309/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Adtran’s Oscilloquartz aPNT+™ platform is a vital tool for keeping critical infrastructure safe and online. (Photo: Business Wire)

“From 5G connectivity to air traffic control, accurate and reliable PNT services are crucial for the safety, efficiency and optimal performance of a wide range of modern applications. That’s why the enhancements we’ve made to our aPNT+ platform are so significant. These include improved jamming and spoofing detection using a unique, highly advanced, dedicated algorithm to ensure maximum resilience against any intentional or unintentional interference,” said Igal Pinhasov, VP of product line management at Oscilloquartz, Adtran. “Our upgraded portfolio is a significant step up for critical network timing. It provides unparalleled precision and reliability even in the most challenging environments, including situations where GNSS is disrupted for extended periods.”

Adtran’s OSA 5401 and 5405 access network synchronization solutions now feature the same advanced jamming and spoofing detection capabilities as its core and edge products. Additionally, the OSA 5405-MB, a compact and integrated outdoor multi-band GNSS receiver and PTP grandmaster, has been upgraded with improved multi-band capabilities. As well as satellite constellations, including GPS, GLONASS, BeiDou and GALILEO, it now supports the Indian Regional Navigation Satellite System (IRNSS). This is critical for mobile network operators in the subcontinent, as the Indian government has ruled that smartphones must be compatible with the country’s home-grown GNSS system. Furthermore, the solution now utilizes a combination of L1 and L5 band signals to better mitigate disruption caused by environmental factors.

“Enhanced NTP functionality is another feature that makes our upgraded aPNT+™ platform even more powerful. Our standalone NTP servers can now support up to 500,000 transactions per second, providing unique NTP performance. This level of transaction handling is a significant advantage against DDoS attacks,” commented Gil Biran, GM of Oscilloquartz, Adtran. “Our core and edge grandmaster clocks are also more resilient than ever. With our multi-source ePRTC combiner, they can leverage up to five independent timing sources, which can include up to three high-performance optical cesium atomic clocks, to create a single super-resilient and highly reliable clock source. Customers can select from GNSS constellations, PTP inputs, and alternative PNT sources such as STL, which uses low Earth orbit satellites, or the terrestrial-based eLORAN. Both offer extra protection against jamming and spoofing attacks while extending the 100nsec holdover period.”

About Adtran

ADTRAN Holdings, Inc. (NASDAQ: ADTN and FSE: QH9) is the parent company of Adtran, Inc., a leading global provider of open, disaggregated networking and communications solutions that enable voice, data, video and internet communications across any network infrastructure. From the cloud edge to the subscriber edge, Adtran empowers communications service providers around the world to manage and scale services that connect people, places and things. Adtran solutions are used by service providers, private enterprises, government organizations and millions of individual users worldwide. ADTRAN Holdings, Inc. is also the largest shareholder of ADVA. Find more at Adtran, LinkedIn and Twitter.

Published by

ADTRAN Holdings, Inc.

www.adtran.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230512005309/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Zambon Announces European Commission Approval of Hopledo® for Adults with Parkinson's Disease and Moderate to Severe Motor Fluctuations28.8.2026 11:00:00 CEST | Press release

Hopledo® is a first-in-class, oral, modified-release formulation of levodopa/carbidopa (LD/CD) approved for the treatment of motor fluctuations of Parkinson’s disease Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026 The approval is based on data from the Phase 3 RISE-PD trial where Hopledo® demonstrated a significant increase in Good ON time compared with immediate-release LD/CD with fewer daily doses and a comparable safety profile Zambon today announced that the European Commission (EC) has granted marketing authorization for Hopledo® (modified-release levodopa/carbidopa) for the treatment of adult patients with Parkinson’s disease and moderate to severe motor fluctuations who have not been sufficiently stabilized with oral levodopa/dopa decarboxylase (DDC) inhibitor-based treatment regimens. Zambon expects to begin the phased introduction of Hopledo® across European markets starting October 2026. The company is working closely

MTG-I2 Safely in Orbit, Unlocking Faster and Sharper Weather Monitoring Across Europe28.8.2026 10:16:00 CEST | Press release

The Meteosat Third Generation Imager 2 satellite (MTG-I2) has successfully passed its first critical post-launch milestones, completing the first full Meteosat Third Generation constellation in orbit. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260828243790/en/ Credit: Arianespace livestream The imager satellite MTG-I2 is safely in orbit and operating as expected following its successful launch yesterday at 22:11 CEST on board an Ariane 6 rocket from Europe’s Spaceport in French Guiana. Our teams have established communication with the spacecraft, which has also deployed its solar panels to ensure its autonomous production of energy. MTG-I2 is in perfect shape to start its Launch and Early Operations Phase that will bring it to a higher orbit, 36 000km above Earth over the following two weeks, where a longer period of calibration and validation of its instruments will begin. This summer’s extreme weather and wildfires hav

New Daiichi Sankyo Data Underscore the Effect of Bempedoic Acid in the Real-World Management of Dyslipidemia and Cardiovascular risk28.8.2026 10:00:00 CEST | Press release

Analyses from the multinational MILOS study show that LDL-C reductions achieved with up to one year of treatment with bempedoic acid-containing therapies translate to a 17.1% relative reduction and a 4.8% absolute reduction in predicted 10-year cardiovascular risk.1 Real-world data demonstrated clinically relevant mean LDL-C reductions of at least 24.9%, regardless of patient gender or glycaemic status, after one year of follow-up.2,3 Findings presented at ESC Congress 2026 reinforce the clinical value of bempedoic acid in routine clinical practice, and demonstrate the continued investment of Daiichi Sankyo in addressing outstanding unmet needs in cardiovascular disease (CVD). Daiichi Sankyo (TSE:4568) today announced new results from the MILOS study that demonstrate the real-world impact of bempedoic acid administered either alone or as a fixed-dose combination with ezetimibe, in the management of dyslipidaemia. Presented at the European Society of Cardiology Congress 2026 in Munich,

TVS Motor Company Appoints Peyman Kargar as Director and Chief Executive Officer28.8.2026 09:31:00 CEST | Press release

Peyman Kargar appointed Director and Chief Executive Officer of TVS Motor Company, effective January 27, 2027 K. N. Radhakrishnan to continue as Director and Chief Executive Officer until then and subsequently will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027 Appointment supports TVS Motor Company's next phase of growth and innovation TVS Motor Company, part of TVS VENU and a leading global manufacturer of two and three-wheelers, today announced the appointment of Peyman Kargar as Director and Chief Executive Officer, effective January 27, 2027. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827012301/en/ Peyman Kargar Peyman will succeed K. N. Radhakrishnan, who will continue in his role until then to ensure a seamless transition. Following the transition, Radhakrishnan will serve as Non-Executive Director up to the date of the ensuing AGM scheduled in July 2027. He has been a

Philips and Imricor Launch Cardiac Interventional MR Lab Solution, Expanding Longstanding Collaboration27.8.2026 21:27:00 CEST | Press release

Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Imricor Medical Systems (ASX: IMR), a pioneer and world-leading developer of MR-compatible products for interventional MR procedures, today announced a new Interventional MR (iMR) lab solution for Philips 1.5T MR. The first commercially available configuration* combines Philips’ 1.5T MRI platform and Imricor's portfolio of iMR systems and consumables, enabling an MR-guided workflow for cardiac intervention, without compromising on MR field strength. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260827693715/en/ Meeting the need for greater tissue insight during cardiac intervention Cardiac arrhythmias affect millions of people worldwide, and catheter ablation is an established and increasingly utilized treatment for many complex cardiac arrhythmias. Yet today, these procedures continue to rely primarily on X-ray fluoroscopy, which provides only

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye